Detailed comparison of efficacy and indications between Trelagliptin and dapagliflozin

Trelagliptin (Trelagliptin) and dapagliflozin (Dapagliflozin) are both oral hypoglycemic drugs commonly used in the management of type 2 diabetes (T2DM), but their mechanisms of action and indications are significantly different. Trelagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4i), which inhibits DPP-4 enzyme activity. It prolongs the half-life of endogenous glucagon-like peptide-1 (GLP-1), enhances insulin secretion from pancreatic β cells and inhibits glucagon secretion from α cells, thereby improving blood sugar control. Dapagliflozin is a sodium -glucose co-transporter 2 inhibitor (SGLT2i). By inhibiting renal tubular glucose reabsorption, it increases urinary glucose excretion and lowers blood sugar. It also has mild diuretic and weight loss effects.

In terms of efficacy, trolagliptin is mainly suitable for patients with mild to moderate elevated blood sugar. It can effectively improve fasting blood sugar and postprandial blood sugar, but its blood sugar reduction range is relatively mild. Usually, each blood sugar drop is about 0.5%-1.0% of HbA1c. The hypoglycemic effect of dapagliflozin depends on renal function and is suitable for patients with normal or mildly reduced renal function. Its HbA1c can be reduced by 0.7%-1.0%, and it also has a positive impact on body weight and blood pressure. Therefore, for patients with type 2 diabetes who are obese or hypertensive, dapagliflozin may have more advantages in improving metabolic syndrome.

In terms of indications, trotagliptin is suitable for monotherapy or in combination with other oral hypoglycemic drugs. It is especially suitable for elderly patients or those with mildly impaired renal function. Its side effects are relatively mild and the risk of hypoglycemia is low. In addition to being used for blood sugar control in type 2 diabetes, dapagliflozin has also been indicated for cardiorenal protection in patients with heart failure and chronic kidney disease. It can significantly reduce the risk of hospitalization for heart failure and the progression of chronic kidney disease. However, its use requires attention to the risks of urogenital infection, hypotension and fluid balance.

Taken together, trotagliptin and dapagliflozin have their own advantages. Trelagliptin is characterized by mildness, good tolerance, and low risk of hypoglycemia, and is suitable for people with mild blood sugar control requirements, with decreased renal function or intoleranceSGLT2iof patients. Dapagliflozin has both hypoglycemic, antihypertensive, weight loss, and cardiorenal protection effects, and is suitable for patients with heavy metabolic burdens and higher cardiorenal risks. In clinical practice, appropriate drugs or combinations of drugs should be selected based on the patient's blood sugar level, concomitant diseases, and tolerance to achieve individualized and precise treatment effects.

Reference link:https://www.drugs.com